Literature DB >> 21697993

Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease.

Paul W Jones1, David Price, Thys van der Molen.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of disability in all its stages, and death in patients with moderate or severe obstruction. At present, COPD is suboptimally managed; current health is often not measured properly and hardly taken into account in management plans, and the future risk for patients with regard to health status and quality of life is not being evaluated. This review addresses the effect of COPD on the lives of patients and examines ways in which existing assessment tools meet physicians' needs for a standardized, simple method to measure consistently the full impact of COPD on patients in routine clinical practice. Current assessment of COPD severity tends to focus on airflow limitation, but this does not capture the full impact of the disease and is not well correlated with patient perception of symptoms and health-related quality of life. Qualitative studies have demonstrated that patients usually consider COPD impact in terms of frequency and severity of symptoms, and physical and emotional wellbeing. However, patients often have difficulty expressing their disease burden and physicians generally have insufficient time to collect this information. Therefore, it is important that methods are implemented to help generate a more complete understanding of the impact of COPD. This can be achieved most efficiently using a quick, reliable, and standardized measure of disease impact, such as a short questionnaire that can be applied in daily clinical practice. Questionnaires are precision instruments that contribute sensitive and specific information, and can potentially help physicians provide optimal care for patients with COPD. Two short, easy-to-use, specific measures, ie, the COPD Assessment Test and the Clinical COPD Questionnaire, enable physicians to assess patients' health status accurately and improve disease management. Such questionnaires provide important measurements that can assist primary care physicians to capture the impact of COPD on patients' daily lives and wellbeing, and improve long-term COPD management.

Entities:  

Keywords:  COPD assessment test; chronic obstructive pulmonary disease; disease management; health status; quality of life; questionnaire

Mesh:

Year:  2011        PMID: 21697993      PMCID: PMC3119104          DOI: 10.2147/COPD.S18181

Source DB:  PubMed          Journal:  Int J Chron Obstruct Pulmon Dis        ISSN: 1176-9106


Background

Chronic obstructive pulmonary disease (COPD) is a major public health problem of high and increasing prevalence,1–5 and is a leading cause of disability in all its stages6,7 and death in patients with moderate or severe obstruction.8–10 COPD imposes a profound burden on patients, including medical emergencies, hospitalizations, work absenteeism, and activity limitations. Ultimately, this has a significant physical and emotional impact on patients.11 COPD, as defined by airflow limitation, is often underdiagnosed12–14 and undertreated,15 leading to poor quality of life for patients.16 Current assessments of COPD severity focus on the amount of air that patients can forcibly exhale from their lungs in the first second of a forced exhalation (FEV1), but this alone does not capture the full impact of the disease.17 As a consequence, patients with COPD are often suboptimally managed.18,19 The future risk for patients with COPD with regard to health status and quality of life is not currently being evaluated routinely, but it is likely that this will provide a marker of both current impact and future risk in these patients.20–24 Improved COPD management requires a range of patient assessments, including lung function, exacerbation episodes, exercise tolerance, and impact on health status. However, patients often have difficulty expressing the burden of their disease and physicians generally do not have sufficient time to collect this information. Therefore, it is important that methods are implemented to enable clinicians to reach a more complete understanding of the impact of the disease on their patients and identify specific needs. The most efficient way to achieve this is to use a quick, reliable, and standardized measure of disease impact, such as a short questionnaire, that can be applied in daily clinical practice to provide physicians with additional useful information. Validated patient-reported outcomes, eg, measurements of health status (health-related quality of life [HRQoL]), or functional status are now recognized as being key in capturing the patient’s experience of important aspects of health in chronic disease.25 Use of these measures will enable physicians to determine what is really important to the individual patient and highlight differences between patients. In conjunction with patient-reported measures, health care systems need to be more organized and focused towards meeting the current and future needs of patients with COPD. Patients with chronic disease require both regular clinician assessments and self-management. Application of the chronic care model, which includes fundamental elements (eg, the community, health care system, and patient self-management) needed to support high-quality care for patients with chronic disease, could potentially improve COPD management.26–28 The management of COPD is now directed towards symptomatic benefit, in terms of improved HRQoL and exercise tolerance, and risk reduction (eg, exacerbations, hospital admissions, and death). Assessment of COPD risk can now be done in routine clinical practice using simple multidimensional prognostic scaling systems, such as the DOSE index.29 The aim of this review, however, is to address the impact of COPD on patients’ lives and to discuss ways in which the new assessment tools can meet physicians’ needs for a standardized, simple method to measure consistently the full impact of COPD on patients in routine clinical practice.

Measuring impact of COPD on patients

The burden of COPD on patients and their families is high.13,30–32 Furthermore, it is not limited to patients with severe COPD, but is also very prominent in younger patients with only mild or moderate airway obstruction, limiting them in their daily lives.33 In general, patients have a restricted understanding of both the extent of their loss of pulmonary function and the severity of their COPD. In the Confronting COPD International Survey, patients’ perceptions of the severity of their COPD did not consistently correspond with the degree of severity indicated by the Medical Research Council (MRC) dyspnea (breathlessness) scale.16 In addition, most patients do not appear to place the same level of importance on their exacerbation episodes as health care providers,34 and a recent study showed that patients generally report smaller changes in HRQoL outcome measures as more clinically meaningful than do physicians.35 Thus, the provision of measures to document clinical outcomes can help both patients and health care providers improve their knowledge about the impact of COPD on patient health. Surveys have indicated that patients usually consider the impact of COPD in terms of symptom frequency and severity, and physical and emotional wellbeing.16 In the Confronting COPD in America survey, 90% of individuals with COPD experienced symptoms either every day or most days during their worst three-month period in the past year (Figure 1).36 Also, patients use language such as “good” and “bad” days to define how COPD influences their HRQoL, so patients’ self-reported assessments are important when evaluating the intensity of symptoms, such as dyspnea and fatigue, and their impact on HRQoL.37
Figure 1

Symptom frequency in individuals with COPD (evaluation of worst three-month period in past year). Patients participating in the Confronting COPD in America survey were asked about the frequency of their symptoms during their worst three-month period in the past year (ie, “Has there been any three-month period in the past year when you experienced … [read item] – every day, most days a week, a few days a week, a few days a month, less than that?”). A high proportion of patients reported that they frequently experienced specific disease-associated outcomes during their worst period in the past year.36

Reproduced with permission from GlaxoSmithKline.

Changing health status

A study in patients with stable COPD showed that changes in health status assessed by patient-reported measures (eg, the St George’s Respiratory Questionnaire [SGRQ], Chronic Respiratory Questionnaire [CRQ], MRC dyspnea scale, and the Hospital Anxiety and Depression Scale [HADS]) worsened significantly over time.38 However, deteriorations in patient-reported outcomes (eg, symptoms, limitation of daily activities, and wellbeing) showed only a weak correlation with changes in physiological indices such as FEV1 and maximal oxygen uptake measured at peak exercise.38 Those authors concluded that to capture the overall deterioration in patients’ health status due to COPD, patient-reported outcomes should be followed independently of physical outcomes.38

Challenges in providing chronic care for patients with COPD

During a consultation, patients tend to understate their disease severity, under-report COPD exacerbations, and do not convey the impact of the disease on their quality of life. In addition, patients often only present to their physicians when their condition has progressed significantly leading to a reduced HRQoL.14,39 Consequently, there is a need to assess patients’ health status to enable optimal disease management.

Clinical assessment questionnaires in COPD

Physicians need to consider several factors when assessing patients with COPD. The impact of COPD depends not only on the degree of airflow limitation but also on the severity of symptoms, systemic effects, and any comorbidities present.2,31 When a patient experiences an exacerbation they often require several weeks of recovery;24 sustained worsening of symptoms can also have a significant impact on patients’ HRQoL and mortality.40–44 Importantly, reductions in objective pulmonary function measurements, such as FEV1, are not well correlated with patients’ perception of symptoms and HRQoL (Figure 2).17,45 When managing patients with COPD it is therefore necessary to measure both pulmonary function and HRQoL.
Figure 2

Relationship between health status as measured by the SGRQ, and FEV1 and GOLD stage. Patients’ perception of symptoms and health-related quality of life, as assessed by the SGRQ, were not well correlated with objective pulmonary function measurements, such as FEV1 and GOLD stage.

Adapted from Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56:880–887 with permission from the BMJ Publishing Group Limited.17

Abbreviations: SGRQ, St George’s Respiratory Questionnaire; FEV1, forced expiratory volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

Physicians require help in realizing the full impact of COPD on their patients. Qualitative studies showed that patients with COPD have difficulty placing themselves along a continuum of disease severity and relating their severity to that of other patients with COPD. During development of the COPD Assessment Test (CAT), patients indicated that they would like to have a method available that would allow them to both assess their own disease severity and communicate this information to their physicians.46 Standardized assessments, beyond peak airflow (maximally forced expiration initiated at full inspiration) currently used to assess patients in clinical practice evaluate multidimensional domains (symptoms, physical, psychological, and social) affected by COPD. Examples of disease-specific instruments include the MRC dyspnea scale, the Clinical COPD Questionnaire (CCQ), and the CAT.46–48 These measures can be assessed in terms of their relative reliability, validity, responsiveness, acceptability, and feasibility in everyday clinical practice.25 Other questionnaires such as the SGRQ, CRQ, and Short Form 36-item Health Survey (SF-36) comprise many more questions and consequently are not suitable for use in daily clinical practice, so these questionnaires are not discussed further. A comprehensive review of available questionnaires is currently being undertaken by the International Primary Care Respiratory Group (www.theipcrg.org/). Questionnaires are precision instruments that can provide sensitive and specific information and, if sufficiently short and simple, can enable physicians in routine clinical practice to assess the health status of their patients accurately, thereby allowing improved COPD management.

Medical research council dyspnea scale

The MRC dyspnea scale, recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD)2 and other national guidelines, was developed by Fletcher et al while studying the respiratory problems of Welsh coalminers in the 1940s.48,49 It is short (comprises five dyspnea items) and has been in use for many years for grading the effect of breathlessness on daily activities. It is simple to administer because it allows patients to indicate the extent to which their breathlessness affects their mobility. However, it only measures one aspect of the patient experience (ie, perceived respiratory disability) and is poorly responsive to change.

Clinical COPD questionnaire

The CCQ (Figure 3) consists of three domains and 10 items, ie, symptoms (four items), functional state (four items), and mental state (two items). All scores range from 0–6 (0, no impairment).47 The CCQ was developed in consultation with 32 patients in two countries, and item reduction performed in collaboration with 79 clinicians worldwide. Patients can complete the CCQ quickly (in approximately two minutes) and it is straightforward to score; this allows data to be instantly collected and processed, enabling its use in everyday practice, clinical trials, and quality-of-care monitoring. Three studies in the Netherlands, Italy, and Sweden provided strong supporting evidence for the reliability, validity, and responsiveness of the CCQ.47,50,51 A change in the total CCQ score of ≥0.4 from one patient visit to the next is considered to be significant (ie, the minimum clinically important difference).52 The CCQ is freely available (in 53 languages) for use in clinical practice (www.ccq.nl).
Figure 3

The clinical COPD questionnaire.

Reproduced with permission from Thys van der Molen.

COPD assessment test

The CAT (Figure 4) is a short (eight-item) and simple-to-administer patient-completed questionnaire designed for routine use in clinical practice. It covers a wide range of effects of COPD, including cough and sputum, chest symptoms, activity limitation, sleep, fatigue, and confidence leaving home. Patients can complete the CAT quickly (in approximately two minutes) by themselves in the doctor’s waiting room. Development of the CAT involved consultation with a large number of patients at each stage of the process. Items covered in the CAT can help physicians measure the overall impact that COPD is having on patient wellbeing and daily life. Thus, the CAT provides a holistic measure of COPD health status;46 it should facilitate a fact-based, physician-patient dialog and improve communication to present a common understanding and grading of the impact of COPD. It is supported by strong evidence for reliability and by preliminary data for construct and discriminant validity;46 additional validity analyses are ongoing. The minimum clinically important difference in CAT score is yet to be established formally,53 but based upon mapping from the SGRQ at a population level it will be approximately 1.6 units. At the individual patient level, a change in CAT score of ≥2 units will be clinically significant. The CAT is freely available (although GlaxoSmithKline owns the copyright to protect it from unauthorized changes) for use in daily clinical practice (www.catestonline.org).
Figure 4

The COPD assessment test.

Reproduced with permission from GlaxoSmithKline.

Summary

An increased understanding of the full impact of COPD on patients and their carers should enable physicians to provide targeted intervention and improve patients’ HRQoL. Care for patients with COPD can be optimized best by use of reliable, standardized measurements of overall disease impact. The measures should be appropriate to the question being addressed, sensitive to changes that are relevant to patients, capable of providing physicians with meaningful scores, and acceptable to both patients and health care providers.54 The questionnaires reviewed here have those attributes and are quick and easy to use during consultations. Incorporation of questionnaires such as these into the consultation process will enable improved patient-physician partnership decision-making, help prioritize patients for primary care review, and drive effective management of patients with COPD.
  49 in total

1.  Chronic disease management: what will it take to improve care for chronic illness?

Authors:  E H Wagner
Journal:  Eff Clin Pract       Date:  1998 Aug-Sep

Review 2.  Health status: what does it mean for payers and patients?

Authors:  Paul W Jones
Journal:  Proc Am Thorac Soc       Date:  2006-05

Review 3.  Measuring the effects of COPD on the patient.

Authors:  Paul Jones; Suzanne Lareau; Donald A Mahler
Journal:  Respir Med       Date:  2005-10-19       Impact factor: 3.415

4.  Seattle Obstructive Lung Disease Questionnaire: sensitivity to outcomes in pulmonary rehabilitation in severe pulmonary illness.

Authors:  Basia Belza; Bonnie G Steele; Kevin Cain; Jeff Coppersmith; JoEllen Howard; Sambasiva Lakshminarayan
Journal:  J Cardiopulm Rehabil       Date:  2005 Mar-Apr       Impact factor: 2.081

5.  Exacerbations of chronic obstructive pulmonary disease--a patients' perspective.

Authors:  Rachel Adams; Niels Chavannes; Kevin Jones; Marianne Stubbe Ostergaard; David Price
Journal:  Prim Care Respir J       Date:  2006-02-28

6.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.

Authors:  J C Bestall; E A Paul; R Garrod; R Garnham; P W Jones; J A Wedzicha
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

7.  Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study.

Authors:  Romain Kessler; Elisabeth Ståhl; Claus Vogelmeier; John Haughney; Elyse Trudeau; Claes-Göran Löfdahl; Martyn R Partridge
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

8.  Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study.

Authors:  Pilar Carrasco Garrido; Javier de Miguel Díez; Javier Rejas Gutiérrez; Antonio Martín Centeno; Elena Gobartt Vázquez; Angel Gil de Miguel; Marta García Carballo; Rodrigo Jiménez García
Journal:  Health Qual Life Outcomes       Date:  2006-05-23       Impact factor: 3.186

9.  Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire.

Authors:  J W H Kocks; M G Tuinenga; S M Uil; J W K van den Berg; E Ståhl; T van der Molen
Journal:  Respir Res       Date:  2006-04-07

10.  Validation of the Clinical COPD questionnaire in Italian language.

Authors:  Salvatore Damato; Chiara Bonatti; Vinicio Frigo; Silvana Pappagallo; Rita Raccanelli; Claudio Rampoldi; Francesco Rodi
Journal:  Health Qual Life Outcomes       Date:  2005-02-07       Impact factor: 3.186

View more
  21 in total

1.  Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland.

Authors:  Brian O'Doherty; Jane Dorman; Karen McGrath; Kevin Kelly; David Molony; Seán Lacey; Sarah Whelan; Simon Schmid; Shane Sullivan
Journal:  Ir J Med Sci       Date:  2019-03-28       Impact factor: 1.568

2.  Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test.

Authors:  Hana Müllerová; Mark T Dransfield; Byron Thomashow; Paul W Jones; Stephen Rennard; Niklas Karlsson; Malin Fageras; Norbert Metzdorf; Stefano Petruzzelli; Jean Rommes; Frank C Sciurba; Maggie Tabberer; Debora Merrill; Ruth Tal-Singer
Journal:  Am J Respir Crit Care Med       Date:  2020-05-01       Impact factor: 21.405

3.  Behavioral medicine approaches to chronic obstructive pulmonary disease.

Authors:  Andreas von Leupoldt; Anja Fritzsche; Ana F Trueba; Alicia E Meuret; Thomas Ritz
Journal:  Ann Behav Med       Date:  2012-08

4.  Evolution of the COPD Assessment Test score during chronic obstructive pulmonary disease exacerbations: determinants and prognostic value.

Authors:  Darwin Feliz-Rodriguez; Santiago Zudaire; Carlos Carpio; Elizabet Martínez; Antonia Gómez-Mendieta; Ana Santiago; Rodolfo Alvarez-Sala; Francisco García-Río
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

5.  Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ).

Authors:  Ioanna G Tsiligianni; Thys van der Molen; Despoina Moraitaki; Ilaine Lopez; Janwillem W H Kocks; Konstantinos Karagiannis; Nikolaos Siafakas; Nikolaos Tzanakis
Journal:  BMC Pulm Med       Date:  2012-05-20       Impact factor: 3.317

Review 6.  Assessment of COPD wellness tools for use in primary care: an IPCRG initiative.

Authors:  Andrew J Cave; Lana Atkinson; Ioanna G Tsiligianni; Alan G Kaplan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-07-17

Review 7.  COPD management: role of symptom assessment in routine clinical practice.

Authors:  Thys van der Molen; Marc Miravitlles; Janwillem W H Kocks
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-10-14

8.  Utility of brief questionnaires of health-related quality of life (Airways Questionnaire 20 and Clinical COPD Questionnaire) to predict exacerbations in patients with asthma and COPD.

Authors:  Marina Blanco-Aparicio; Isabel Vázquez; Salvador Pita-Fernández; Sonia Pértega-Diaz; Héctor Verea-Hernando
Journal:  Health Qual Life Outcomes       Date:  2013-05-27       Impact factor: 3.186

9.  Portuguese-language version of the COPD Assessment Test: validation for use in Brazil.

Authors:  Guilherme Pinheiro Ferreira da Silva; Maria Tereza Aguiar Pessoa Morano; Cyntia Maria Sampaio Viana; Clarissa Bentes de Araujo Magalhães; Eanes Delgado Barros Pereira
Journal:  J Bras Pneumol       Date:  2013 Jun-Aug       Impact factor: 2.624

10.  Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease.

Authors:  Claire Brockwell; Sundari Ampikaipakan; Darren W Sexton; David Price; Daryl Freeman; Mike Thomas; Muzammil Ali; Andrew M Wilson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.